폐 편평세포암종 내 Leucine-Rich Repeat Kinase 2 암촉진 효과와 Interleukin-10 발현과의 연관성 = Correlation of Protumor Effects of Leucine-Rich Repeat Kinase 2 with Interleukin-10 Expression in Lung Squamous Cell Carcinoma

국문 초록 (Abstract)

Leucine-rich repeat kinase 2 (LRRK2)는 파킨슨병과 같은 신경퇴행성 질환의 병태생리학적인 측면에서 중요한 역할을하는 것으로 알려져 있고 주로 뇌뿐만 아니라 폐에서도 발현된다. 그러나 LRRK2 발현이 폐 편평세포암(lung squamous cell carcinoma, LUSC)과 같은 일반적인 폐암의 아형과 병인성이있는지는 불분명하다. 본 연구에서는 Kaplan Meier 플로터 생물정보학 온라인 도구를 사용하여 폐 편평세포암종 내에서LRRK2와의 예후 진단가치를 분석하였다. 폐 편평세포암종 환자는 LRRK2의 발현이 높아지면 더 나쁜 예후를 나타낸다고 알려져 왔다. LRRK2 발현이 높은 환자의 경우 종양 돌연변이 부담, 높은 신항원부하, 더 나쁜 생존율, 성별과 상관관계를 보였다. 더욱이, gene expression profiling interactive analysis 데이터분석에서 높은 LRRK2 발현을 가진 환자에서의 심각한증상은 항염증성 사이토카인(예, IL-4, IL-10 )의 높은 발현에 양의 상관관계를 보였지만 염증성 사이토카인은 상관성이 없었다.
이러한 결과에서 IL-10관련 유전자의 높은 발현은 더 나쁜 예후를 보이는 LRRK2-high 환자들에서 유의미하게 연관성을 보였다. 또한, tumor immunity estimation resource 데이터는큰포식세포가 LRRK2-high LUSC환자에서 IL-10의 기원세포중 하나임을 보여주었다. 본 연구를 통해 결과적으로 LRRK2-IL10 축의 가설이 LUSC 환자의 잠재적이 치료 표적과 예후 바이오 마커일 수 있음을 보여주었다.

참고문헌 (Reference)

• 1 Lánczky A, "Web-based survival analysis tool tailored for medical research(KMplot) : development and implementation" 23 : e27633-, 2021
• 2 Das LM, "Vitamin D improves sunburns by increasing autophagy in M2 macrophages" 15 : 813-826, 2019
• 3 Ischenko I, "Transforming growth factor-beta signaling network regulates plasticity and lineage commitment of lung cancer cells" 21 : 1218-1228, 2014
• 4 Ley S, "The role of TRKA signaling in IL-10 production by apoptotic tumor cell-activated macrophages" 32 : 631-640, 2013
• 5 Liu Z, "The kinase LRRK2 is a regulator of the transcription factor NFAT that modulates the severity of inflammatory bowel disease" 12 : 1063-1070, 2011
• 6 Li T, "TIMER : a web server for comprehensive analysis of tumor-infiltrating immune cells" 77 : e108-e110, 2017
• 7 Szklarczyk D, "STRING v11 : protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets" 47 (47): D607-D613, 2019
• 8 Thévenet J, "Regulation of LRRK2 expression points to a functional role in human monocyte maturation" 6 : e21519-, 2011
• 9 Hakimi M, "Parkinson’s disease-linked LRRK2 is expressed in circulating and tissue immune cells and upregulated following recognition of microbial structures" 118 : 795-808, 2011
• 10 Dauer W, "Parkinson’s disease : mechanisms and models" 39 : 889-909, 2003
• 11 Gessner A, "Mast cells, basophils, and eosinophils acquire constitutive IL-4 and IL-13 transcripts during lineage differentiation that are sufficient for rapid cytokine production" 174 : 1063-1072, 2005
• 12 Rigoni A, "Mast cells, basophils and eosinophils : from allergy to cancer" 35 : 29-34, 2018
• 13 Zeni E, "Macrophage expression of interleukin-10 is a prognostic factor in nonsmall cell lung cancer" 30 : 627-632, 2007
• 14 Yunna C, "Macrophage M1/M2polarization" 877 : 173090-, 2020
• 15 Faruki H, "Lung adenocarcinoma and squamous cell carcinoma gene expression subtypes demonstrate significant differences in tumor immune landscape" 12 : 943-953, 2017
• 16 Chen JW, "Lung adenocarcinoma and lung squamous cell carcinoma cancer classification, biomarker identification, and gene expression analysis using overlapping feature selection methods" 11 : 13323-, 2021
• 17 Lebovitz C, "Loss of Parkinson’s susceptibility gene LRRK2 promotes carcinogen-induced lung tumorigenesis" 11 : 2097-, 2021
• 18 Cardoso CC, "Leprosy susceptibility : genetic variations regulate innate and adaptive immunity, and disease outcome" 6 : 533-549, 2011
• 19 Herzig MC, "LRRK2 protein levels are determined by kinase function and are crucial for kidney and lung homeostasis in mice" 20 : 4209-4223, 2011
• 20 Tian Y, "LRRK2 plays essential roles in maintaining lung homeostasis and preventing the development of pulmonary fibrosis" 118 : e2106685118-, 2021
• 21 Yang C, "LRRK2 is a candi-date prognostic biomarker for clear cell renal cell carcinoma" 21 : 343-, 2021
• 22 Tolosa E, "LRRK2 in Parkinson disease : challenges of clinical trials" 16 : 97-107, 2020
• 23 Ma Q, "Identification and validation of key genes associated with non-small-cell lung cancer" 234 : 22742-22752, 2019
• 24 Celik MÖ, "IL-4 induces M2 macrophages to produce sustained analgesia via opioids" 5 : e133093-, 2020
• 25 Tang Z, "GEPIA : a web server for cancer and normal gene expression profiling and interactive analyses" 45 (45): W98-W102, 2017
• 26 Wang J, "Dysregulated Th1 cells in lung squamous cell carcinoma" 112 : 1567-1576, 2022
• 27 Huang T, "Distinguishing lung adenocarcinoma from lung squamous cell carcinoma by two hypomethylated and three hypermethylated genes : a meta-analysis" 11 : e0149088-, 2016
• 28 Li B, "Comprehensive analyses of tumor immunity : implications for cancer immunotherapy" 17 : 174-, 2016
• 29 Hatanaka H, "Clinical implications of interleukin(IL)-10 induced by non-small-cell lung cancer" 11 : 815-819, 2000
• 30 Margarida Saraiva, "Biology and therapeutic potential of interleukin-10" Rockefeller University Press 217 (217): 2019
• 31 Giasson BI, "Biochemical and pathological characterization of Lrrk2" 59 : 315-322, 2006
• 32 Gordon S, "Alternative activation of macrophages : mechanism and functions" 32 : 593-604, 2010